Table 4 Trial patient data by outcome
Author | Mortality | Mortality | Shock-reversal | Shock-reversal | Corticotrophin | Corticotrophin | Shock-reversal | Shock-reversal | Shock-reversal | Shock-reversal | Superinfection | Superinfection | GIS bleed | GIS bleed | New | New |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Hospital | Hospital | days(7-28) | days(7-28) | responders | responders | responders | responders | non-responders | non-responders | Â | Â | Â | Â | hyperglycaemia | hyperglycaemia |
| Â | n/total | n/total | n/total | n/total | Â | Â | Days (7-28) | Days (7-28) | Days (7-28) | Days (7-28) | Â | Â | Â | Â | Â | Â |
| Â | Steroid | Placebo | Steroid | Placebo | Steroid | Placebo | Steroid | Placebo | Steroid | Placebo | Steroid | Placebo | Steroid | Placebo | Steroid | Placebo |
Cooperative StudyGroup [32] | 54/96 | 32/98 | NA | NA | Â | Â | Â | Â | Â | Â | 3/96 | 3/99 | 4/96 | 0/98 | NA | NA |
Klastersky and colleagues [41] | 24/66 | 18/39 | NA | NA | Â | Â | Â | Â | Â | Â | 11/46 | 6/39 | NA | NA | NA | NA |
Schumer [31] | 9/86 | 33/86 | NA | NA | Â | Â | Â | Â | Â | Â | Â | Â | 2/86 | 1/86 | 1/86 | 1/86 |
Sprung and colleagues [43] | 33/43 | 11/16 | 25/43 | 6/16 | Â | Â | Â | Â | Â | Â | 11/43 | 1/16 | 1/43 | 2/32 | 4/45 | 0/16 |
Bone and colleagues [38] | 65/191 | 48/190 | 85/130 | 83/114 | Â | Â | Â | Â | Â | Â | 29/152 | 30/147 | NA | NA | NA | NA |
Luce and colleagues [46] | 22/38 | 20/37 | NA | NA | Â | Â | Â | Â | Â | Â | 3/38 | 4/37 | 18/38 | 16/37 | 16/38 | 15/37 |
Bollaert and colleagues [37]## | 7/22 | 12/19 | 15/22 | 4/23 | 18/22 | 11/19 | 12/18 | 2/11 | 3/4 | 2/8 | 7/22 | 9/19 | 1/22 | 3/19 | 3/22 | 3/19 |
Briegel and colleagues [39] | 5/20 | 6/20 | 18/20 | 16/20 | NA | NA | NA | NA | NA | NA | 10/20 | 7/20 | 1/20 | 0/20 | NA | NA |
Chawla and colleagues [47]# | 6/23 | 10/21 | 16/23 | 7/21 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
Yildiz and colleagues [45] | 8/20 | 12/20 | NA | NA | 15/20 | 11/20 | NA | NA | NA | NA | 0/20 | 1/20 | NA | NA | 0/20 | 0/20 |
Annane and colleagues [36] | 95/160 | 103/150 | 60/151 | 40/149 | 36/150 | 34/149 | 18/36 | 18/34 | 65/114 | 46/115 | 22/150 | 27/150 | 11/150 | 8/149 | NA | NA |
Tandan and colleagues [44] | 11/14 | 13/14 | 5/14 | 3/14 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
Oppert and colleagues [42] | 7/18 | 11/23 | 13/18 | 18/23 | 6/18 | 9/23 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
Sprung and colleagues [8] | 111/251 | 100/245 | 200/251 | 184/248 | 118/243 | 136/244 | 100/118 | 104/136 | 98/125 | 76/108 | 78/234 | 61/132 | 15/234 | 13/232 | 186/234 | 161/232 |